Regenerative options for orthopedic & sports medicine.
Perinatal MSCs, amniotic allografts, PRP, focused shockwave, and Class IV laser — matched to musculoskeletal indications with practice-ready protocols.
Orthopedic and sports medicine practices work across the widest indication range in regenerative medicine — from OA and tendinopathy to post-arthroscopic recovery and return-to-play. DRS supports device selection, biologics sourcing, and combination protocols (e.g., ECSWT + PRP, HPLT + MSC) with documented evidence tiers.
Common indications we support
- Knee, hip, and shoulder osteoarthritis
- Rotator cuff and Achilles tendinopathy
- Plantar fasciitis and lateral epicondylitis
- Ligament sprains and post-surgical recovery
- Chronic low back pain (facet, disc adjunct)
- Return-to-play acceleration in athletes
Devices, biologics & protocols for this specialty
Wharton's jelly and cord-tissue products from FDA-registered tissue banks under 21 CFR Part 1271.
MSC biologicsDehydrated and cryopreserved matrices for tendinopathy, joint capsule augmentation, and post-arthroscopic use.
Amniotic options1,100+ indexed orthopedic trials — devices, transducers, and protocols for MSK pain.
ECSWT platforms10 – 30 W near-infrared laser adopted by 40+ pro sports teams and DoD/VA rehab programs.
HPLT devicesPublications relevant to this specialty
Curated evidence from our Publications library that references Regenerative options for orthopedic & sports medicine.
- Energy-based devices · Orthopedic, urologic, cardiacExtracorporeal Shockwave Therapy (ECSWT)
Focused and radial extracorporeal shockwave therapy uses short, high-energy acoustic pulses to trigger mechanotransduction, neovascularization, and controlled inflammation. The 2026 literature indexes more than 1,100 randomized or comparative trials across orthopedic, urologic, and cardiovascular indications.
Why it's relevant: 1,100+ indexed MSK trials — plantar fasciitis, tendinopathy, and OA.
Read the publication - Photobiomodulation · Class IVHigh Power Laser Therapy (HPLT)
Class IV therapeutic lasers deliver 10 – 30 W of near-infrared light at 810 – 1,064 nm, driving photobiomodulation of cytochrome c oxidase and short-term ATP surge. The 2026 evidence includes controlled trials from major U.S. medical schools, the DoD, VA rehabilitation programs, and adoption by 40+ NFL, NBA, and MLB training rooms.
Why it's relevant: Adopted by 40+ pro sports teams and DoD/VA rehab programs.
Read the publication - Cell-based biologics · Wharton's jelly, UCBPerinatal Mesenchymal Stem Cell Biologics
Perinatal mesenchymal stem cells — sourced from Wharton's jelly, umbilical cord blood, and placental tissue — are increasingly favored over adult autologous MSCs for immunomodulatory potency and yield. 2026 secretome analyses show 3–10× higher expression of key regenerative cytokines than age-matched adult MSCs.
Why it's relevant: Wharton's jelly and cord-tissue products for OA, tendinopathy, and post-surgical use.
Read the publication - Biologic dressings · Regenerative matricesAmniotic Tissue Allografts
Amniotic tissue has been used clinically for more than 100 years, since Davis first documented amniotic-membrane skin grafts in 1910. Modern dehydrated and cryopreserved allografts retain growth factors, cytokines, and extracellular matrix that support wound healing, ophthalmic reconstruction, and orthopedic soft-tissue repair.
Why it's relevant: Tendinopathy, joint capsule augmentation, and post-arthroscopic use.
Read the publication - Extracellular vesicles · Standardized reportingExosome Characterization & MISEV 2023 Standards
Exosomes are 30 – 150 nm extracellular vesicles that carry proteins, lipids, and RNA cargo between cells. MISEV 2023 — the third revision of Minimum Information for Studies of Extracellular Vesicles from the International Society for Extracellular Vesicles — is the current global standard for characterization and reporting.
Why it's relevant: Combination workflows with MSCs, PRP, and ECSWT.
Read the publication
Frequently asked questions
- Does PRP help knee osteoarthritis?
- Multiple randomized trials and meta-analyses show PRP outperforming hyaluronic acid and saline for pain and function at 6 to 12 months in mild-to-moderate knee osteoarthritis. Advanced bone-on-bone disease responds far less predictably.
- How do PRP and cell-based biologics differ?
- PRP is autologous, same-day, and minimally manipulated. Cell-based and amniotic-derived products are manufactured, carry distinct regulatory pathways, and require careful sourcing and documentation.
- Where does shockwave fit in orthopedics?
- Focused and radial shockwave have the strongest evidence in chronic tendinopathy — plantar fasciitis, lateral epicondylitis, calcific shoulder tendinopathy — often as a first-line alternative to injection.
- Are these treatments an alternative to joint replacement?
- They are not a substitute for arthroplasty in end-stage disease. Their role is delaying or avoiding surgery in earlier-stage degeneration and treating soft-tissue pain that has failed conservative care.
Bring regenerative medicine into your practice.
Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.